TNFRSF18 and neoplasm: Although GITR stimulation primarily enhances the proliferation of Treg cells, several studies suggest that may not be the case in the context of cancer; instead, GITR agonists reduce tumor growth by increasing effector T cells and reducing Treg cells [68,69,70].